Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020

Michael Anne Kyle; Stacie B Dusetzina; Nancy L Keating

doi:10.1001/jamanetworkopen.2022.21468

Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020

JAMA Netw Open. 2022 Jul 1;5(7):e2221468. doi: 10.1001/jamanetworkopen.2022.21468.

Authors

Michael Anne Kyle¹, Stacie B Dusetzina^{2

3}, Nancy L Keating^{1

4}

Affiliations

¹ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
² Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
⁴ Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Abstract

This cross-sectional study examines trends in drug spending in Medicare Parts B and D and describes the share of total use and spending attributed to oncology drugs within each program.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Health Expenditures*
Humans
Medicare*
United States

Grants and funding

T32 CA092203/CA/NCI NIH HHS/United States